白云山公告称，附属企业广药二期基金与广药资本、广开基金合作设立广药广开基金，投资9750万元。 该基金于2026年1月8日完成工商登记，各合伙人实缴首期出资1.2亿元，1月30日在中国证券投资基金业 协会完成备案。本次投资符合广药二期基金投资方向，利于扩大规模、分散风险等。截至目前，公司与 私募基金合作投资合计5.87亿元。 ...

Core Viewpoint - The recent performance of the Chinese medicine sector, particularly the Chinese Medicine ETF (560080), indicates a potential shift in investment style, with increasing capital inflow and favorable valuation metrics suggesting a recovery phase ahead for the industry [3][8]. Group 1: Market Performance - On February 2, the Shanghai Composite Index fell by 2.48%, while the Chinese Medicine ETF (560080) experienced a decline of 1.24%, with a total trading volume exceeding 70 million yuan [1]. - The Chinese Medicine ETF has seen continuous capital inflow, accumulating over 100 million yuan in net inflow over the past five days [1][3]. Group 2: Valuation Metrics - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the Chinese Medicine ETF is 23.96, indicating that the valuation is below 85.61% of the time since its inception in May 2015, highlighting attractive valuation opportunities [3]. - The Chinese medicine sector is perceived to be entering a "sweet spot" in terms of valuation, with a significant portion of stocks showing potential for recovery [3]. Group 3: Individual Stock Performance - Most of the weighted stocks in the Chinese Medicine ETF index closed lower, with notable declines including Jilin Aodong down over 7% and Darentang down over 3% [5]. - Conversely, Dong'e Ejiao was one of the few stocks that rose, gaining over 1% [5]. Group 4: Earnings Forecasts - Jilin Aodong has projected a net profit of approximately 2.265 to 2.482 billion yuan for 2025, representing a year-on-year growth of 46.0% to 60.0%, attributed to increased fair value changes and investment income [7]. - As of January 31, 11 companies within the Chinese Medicine ETF index have released earnings forecasts, with six reporting positive year-on-year growth [7]. Group 5: Future Outlook - The Chinese medicine sector is expected to experience a rebound in 2026, driven by inventory digestion and an anticipated increase in flu incidence in Q4 2025, which may enhance sales of related OTC products [8]. - The potential update of the essential drug catalog is also seen as a catalyst for growth, with companies that can meet the new criteria likely to benefit [8]. Group 6: Investment Themes - Three main investment themes have been identified for the Chinese medicine industry: price governance, consumption recovery, and state-owned enterprise reform [9][10][11]. - The focus on price governance suggests that companies with competitive advantages may benefit from price reductions leading to increased market share [9]. - The recovery of consumer demand, driven by macroeconomic improvement and an aging population, is expected to support sales growth in the Chinese medicine sector [10]. - State-owned enterprises in the industry are anticipated to present investment opportunities as reforms aim to enhance efficiency and performance [11].

Core Insights - The Regional Comprehensive Economic Partnership (RCEP) has been effective for four years, benefiting enterprises in Beijing with significant tariff reductions and increased import values [1][2] Group 1: Economic Impact - Since the RCEP's implementation, Beijing enterprises have enjoyed a cumulative import value of 15.38 billion yuan and a tax reduction of 652 million yuan [2] - In 2025, the enjoyed import value is projected to reach 5.175 billion yuan, with a tax reduction of 237 million yuan, representing increases of 161% and 230% respectively compared to 2022 [2] Group 2: Export Certification - Beijing Customs has issued a total of 109,400 certificates of origin for exports to RCEP countries, amounting to 56.157 billion yuan [2] - In 2025, the number of certificates issued is expected to be 31,224, with a value of 14.831 billion yuan, reflecting growth rates of 30.32% and 11.77% compared to 2022 [2] Group 3: Efficiency Improvements - The implementation of intelligent review for export certificates allows for 24/7 processing, with 70% of RCEP certificates being approved instantly and over 90% being self-printed [2] - The approved exporter system enables companies to issue their own origin declarations, reducing the need for traditional certificates and expediting the shipping process [2][3]

Investment Rating - The report assigns a "Buy" rating for the company, Tian Shi Li (600535), marking its first coverage [2]. Core Insights - The company has joined the China Resources Group, initiating a new growth chapter. It has established a business structure that integrates modern traditional Chinese medicine, biological drugs, and chemical drugs, with a focus on prescription drugs and innovation-driven research and development [7][20]. - The report anticipates revenue growth from 85.35 billion yuan in 2025 to 93.70 billion yuan in 2027, with corresponding net profits expected to rise from 9.90 billion yuan to 13.49 billion yuan during the same period [10]. - The company is well-positioned in the cardiovascular market, with its core product, Compound Danshen Dripping Pills, leading in market share and undergoing further development for new indications [9][50]. Summary by Sections 1. Company Overview - Tian Shi Li has evolved from a single product focus to a diversified portfolio that includes modern traditional Chinese medicine, biological drugs, and chemical drugs, supported by a strong emphasis on innovation and internationalization [18][20]. - The company has undergone significant changes, including a shift in control to China Resources Group, which is expected to enhance its operational capabilities and market reach [39][40]. 2. Product Development and Market Position - The company has a comprehensive product matrix in the cardiovascular field, with key products like Compound Danshen Dripping Pills and Qi Shen Yi Qi Pills, which are undergoing clinical trials for new indications [41][48]. - The cardiovascular traditional Chinese medicine market is substantial, with a projected size of 50.5 billion yuan by 2024, and Tian Shi Li holds a leading position with a market share of 7.5% for its flagship product [46][48]. 3. Financial Projections - Revenue projections for 2025-2027 are 85.35 billion, 88.96 billion, and 93.70 billion yuan, with net profits expected to be 9.90 billion, 11.95 billion, and 13.49 billion yuan respectively, indicating a stable growth trajectory [10][29]. - The report estimates a target market capitalization of 28.083 billion yuan for 2026, reflecting a 24% upside potential from the current market value [10]. 4. Innovation and R&D - The company is actively pursuing innovation in both traditional and biological drug sectors, with several products in late-stage clinical trials, including those targeting chronic diseases and metabolic disorders [9][11]. - The introduction of new indications for existing products, such as the expansion of Compound Danshen Dripping Pills to include diabetic retinopathy, is expected to drive future growth [50].

Market Overview - The Chinese medicine sector experienced a decline of 0.98% on February 2, with Jilin Aodong leading the drop [1] - The Shanghai Composite Index closed at 4015.75, down 2.48%, while the Shenzhen Component Index closed at 13824.35, down 2.69% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 27.93, up 6.68% [1] - Foci Pharmaceutical (002644) with a closing price of 9.21, up 4.66% [1] - Significant decliners included: - Jilin Aodong (000623) with a closing price of 18.88, down 7.63% [2] - Datang Pharmaceutical (920433) with a closing price of 5.86, down 3.46% [2] Trading Volume and Capital Flow - The Chinese medicine sector saw a net outflow of 235 million yuan from institutional investors, while retail investors contributed a net inflow of approximately 51.97 million yuan [2] - The trading volume for Jilin Aodong reached 504,800 shares, with a transaction value of 977 million yuan [2] Individual Stock Capital Flow - Key capital flows for selected stocks included: - Dong'e Ejiao (000423) with a net inflow of 129 million yuan from institutional investors, but a net outflow of 18.04 million yuan from retail investors [3] - Foci Pharmaceutical (002644) had a net inflow of 43.42 million yuan from institutional investors, with a net outflow of 15.68 million yuan from retail investors [3]

Group 1 - The company is closely monitoring the development of new treatment technologies for joint pain and muscle strain [1] - The company is actively conducting trend analysis and planning in related fields to seize market opportunities and enhance its competitive advantage [1] - The company is continuously expanding the application scenarios of its pain relief patches [1]

江西省市场监管局多维帮扶助企获质量领域殊荣 □ 本报记者 李培晞 走进江中药业股份有限公司（以下简称"江中药业"）的"零碳工厂"，智能化生产线正有序运转，中药材 从投料提取到包装仓储的全流程质控数据实时跳动在中控屏幕上…… 转自：中国质量报 "此次的殊荣离不开江西省市场监管局的精准帮扶，是政策引导与企业实践双向奔赴的成果。"江西钨业 控股集团相关负责人在采访中感慨道。在卓越绩效管理模式落地过程中，江西省市场监管局迅速组建专 家团队上门问诊，开展标准宣贯培训，结合该集团"资源为本、深化加工"战略，量身定制全流程提升方 案，从质量管理体系优化、申报材料打磨，到工艺指标攻关、质量文化培育，全程提供专业指导。这份 帮扶也转化为亮眼实绩，该集团主导参与195项国家及行业标准的制修订，28项产品获评"赣出精品"， 实现了经济效益与生态效益双赢。 育良才 质为梯 攀高峰 "在市场监管部门的悉心指导与大力支持下，我们创新建立了'233'中药绿色智造质量管理模式，探索解 决中药共性难题，将'药材好，药才好'的初心转化为可落地、可复制的质量管控标准，助力中医药产业 健康发展。"江中药业质量相关负责人说。 近日，2025年度江西省 ...

发布时间：2026-02-02 行业投资评级 强于大市|维持 | 行业基本情况 | | | --- | --- | | 收盘点位 | 8338.3 | | 52 周最高 | 9323.49 | | 52 周最低 | 6876.88 | 行业相对指数表现 -5% -1% 3% 7% 11% 15% 19% 23% 27% 31% 2025-02 2025-04 2025-06 2025-09 2025-11 2026-01 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 分析师:徐智敏 SAC 登记编号:S1340525100003 Email: xuzhimin@cnpsec.com 近期研究报告 2025 年有数十个 AI 衍生的管线进入人体临床试验，但回顾过往 管线来看，与任何其他新技术的发展一样，AI 制药的发展之路也是曲 折的。AI 制药极大加速了临床早期的进程同时亦能取得超出传统经验 水平的 1 期成功率（80%~90% vs 40%~65%），而在 2 期及后续的进 ...

Core Viewpoint - The article emphasizes the importance of health and wellness, particularly for individuals over 40, highlighting the need to take care of oneself to support family responsibilities and well-being [5][8][9]. Group 1: Health and Wellness - Individuals over 40 who have healthy parents and a stable family are considered to be at the top of the social pyramid [5]. - Taking care of one's health is not just a personal matter but a significant concern for the entire family [9]. - True wellness is described as a long-term commitment rather than a temporary trend or luxury [11]. Group 2: Yunnan Baiyao Brand - Yunnan Baiyao is presented as a century-old national brand, established in 1902, known for its quality and trustworthiness [15][16]. - The brand has a rich history, having been recognized and supported by historical figures, including Premier Zhou Enlai [18]. - Yunnan Baiyao's products are based on a secret formula that has been validated by generations of users, establishing a strong reputation [21]. Group 3: Product Offerings - The article promotes various health products, including broken wall ganoderma spore powder, western ginseng, and saffron, available at discounted prices during a live broadcast event [13][28]. - The broken wall ganoderma spore powder is highlighted for its high bioavailability and health benefits, including immune support and anti-aging properties [40][41]. - The article also mentions the three-seven powder, which is known for its blood circulation benefits, and emphasizes its quality through rigorous testing [54][56]. Group 4: Promotional Event - A promotional live broadcast event is scheduled for February 4, featuring significant discounts on health products, encouraging early reservations [27][28]. - The event aims to provide affordable health solutions, with prices as low as 9.9 yuan for certain products, making them accessible to a wider audience [28][29]. - The article encourages participation in the live event to secure exclusive offers and learn about the products from experts [27][76].

Core Viewpoint - The official release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant step in the internationalization and standardization of traditional Chinese medicine (TCM), providing a unified framework for the global industry [5][7]. Group 1: Standard Release and Significance - The ISO international standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" was officially released during a seminar focused on the high-quality international development of TCM [5]. - This standard establishes a comprehensive standardization system for the global broken wall Ganoderma spore powder industry, covering aspects from raw materials to production processes and quality control [7]. - The standard sets a minimum requirement of ≥95% wall-breaking rate and introduces a multi-index evaluation system for active components, ensuring both traditional practices and modern technology are integrated [7]. Group 2: Impact on Consumers and Industry - For consumers, the standard provides a more reliable product guarantee, enabling better assessment of product safety and effectiveness, and helping to distinguish genuine products from counterfeits [7]. - The company, Shouxiangu, has been a key player in TCM standardization, having led or participated in the formulation of over 100 TCM standards, including 8 international standards [7][8]. Group 3: Future Directions and Challenges - The standardization initiative is expected to drive the internationalization of TCM, with a focus on quality and safety, while also addressing the unique challenges posed by the traditional practices of TCM [9][10]. - Experts emphasize the need for a balance between standardization and the unique characteristics of TCM, advocating for a system that integrates traditional wisdom with modern scientific approaches [10][11]. - The seminar highlighted the importance of protecting authentic medicinal materials and educating international markets as key factors in promoting the internationalization of TCM [11].